What is Aignostics?
Aignostics operates at the vanguard of the precision medicine revolution, utilizing interdisciplinary expertise to advance the fields of AI and pathology. The company specializes in developing sophisticated computational tools that enable researchers and clinicians to derive deeper insights from tissue samples, thereby enhancing the accuracy and efficiency of diagnostic processes. By integrating deep tech with medical research, Aignostics is positioned to redefine standards in drug development and personalized patient care, serving as a critical partner for pharmaceutical and clinical organizations worldwide.
How much funding has Aignostics raised?
Aignostics has raised a total of $48M across 2 funding rounds:
Series A
$14M
Series B
$34M
Series A (2022): $14M with participation from Wellington Partners, VC Fonds Technologie, Boehringer Ingelheim Venture Fund, and High-Tech Gründerfonds
Series B (2024): $34M led by Mayo Clinic, IBB Ventures, Boehringer Ingelheim Venture Fund, Wellington Partners, CARMA FUND Management, and ATHOS Holding
Key Investors in Aignostics
Mayo Clinic
A nonprofit global healthcare organization renowned for its integrated clinical practice, medical research, and commitment to advancing complex patient care through multidisciplinary innovation.
Boehringer Ingelheim Venture Fund
A corporate venture arm focused on pioneering science and first-in-class therapeutics, leveraging deep pharmaceutical R&D expertise to support high-potential life science startups.
Wellington Partners
A prominent European venture capital firm specializing in early- and growth-stage investments across the life sciences, digital health, and medical technology sectors.
What's next for Aignostics?
With the successful closure of this major enterprise-level funding, Aignostics is well-positioned to transition into a phase of rapid commercial expansion and technological refinement. The strategic focus will likely center on broadening the application of its AI-pathology platform across diverse therapeutic areas and strengthening its collaborative network with global healthcare institutions. As the company scales, the emphasis will remain on maintaining rigorous scientific standards while navigating the complex regulatory landscape of digital health. This capital provides the necessary runway to accelerate product development cycles and solidify the company's role as an indispensable infrastructure provider in the future of precision diagnostics.
See full Aignostics company page
